Adverity, a Vienna, Austria-based data analytics company targeting applications in media, marketing, and ecommerce areas, raised $30m in Series C financing.
Refurbed, an Austrian marketplace for refurbished electronics promoting sustainable consumption, raised $17m in Series A funding.
Mostly AI, a Vienna, Austria-based synthetic data startup, raised $5M in Series A funding.
Speedinvest, a pan-European early-stage venture capital firm, closed its third institutional fund, at €190m.
Innerspace, a Wattens, Innsbruck, Austria-based virtual reality startup, raised an over €1m growth funding round.
Tricentis, a Mountain View, Calif.-based leader in continuous testing for DevOps, acquired SpecFlow, a Behaviour Driven Development solution for .NET developers around the world.
Anyline, a Vienna, Austria-based provider of Optical Character Recognition (OCR) technology, raised $12m in Series A funding.
TTTech Auto, a provider of safety software platforms for automated driving and beyond, acquired Turkish automotive software company Red Pine Software.
Themis, a Vienna, Austria-based developer of a vaccine for Chikungunya, secured €40M in Series D financing.
kompany, a Vienna, Austria-based RegTech platform for Global Business Verification and Business KYC, raised a funding round of undisclosed amount.
Ever Pharma Holding Ges.m.b.H, a Salzburg, Austria-based a fully integrated specialty pharmaceuticals company, acquired Amneal Deutschland GmbH, a subsidiary of Amneal Pharmaceuticals that operates the company’s commercial operations in Germany.
HQ Equita, HQ Capital’s private equity direct investment arm, closed its fifth fund, HQ Equita V, with capital commitments totaling €308m.
euNetworks Group, a Western European bandwidth infrastructure company, acquired Onstage Online GmbH, a Vienna, Austria-based fibre company.
Helsinki, Finland-based Invesdor Oy and Vienna, Austria-based Finnest GmbH merged their businesses to create a Paneuropean digital financing and investing platform.
Hookipa Pharma Inc., a NYC- and Vienna, Austria-based company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform, completed a $37.4m (€33.2m) Series D financing.